Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized sensitivity-directed combination chemotherapy vs dacarbazine in first-line stage IV metastatic melanoma
2008-001686-28Phase 3Terminated
- Sponsor
- Julius-Maximilians-Universität Würzburg
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of dacarbazine in melanoma (2 arms), sponsored by Julius-Maximilians-Universität Würzburg. Primary endpoint: Disease-specific overall survival. Started Apr 2008; status: terminated.
02
Drugs
dacarbazine
03
Conditions
melanoma
Beyond the preview
Go deeper on 2008-001686-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001686-28.